Oligomer-specific amyloid beta epitope and antibodies

Patent metadata

Field	Value
Publication number	US-9849165-B2
Application number	US-201514971529-A
Country	US
Kind code	B2
Filing date	Dec 16, 2015
Priority date	Mar 3, 2010
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

A novel constrained peptide epitope derived from Aβ, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is also described. Methods of treating, preventing, and diagnosing Alzheimer's disease are also described.

First claim

What is claimed is:

1. An antigenic peptide comprising a conformational epitope having a constrained cyclic configuration, wherein the conformational epitope has an amino acid sequence of at least SNK corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ, and wherein the K (Lysine) is solvent-exposed.

2. The antigenic peptide of claim 1 , wherein the conformational epitope has an amino acid sequence corresponding to SEQ ID NO: 1.

3. The antigenic peptide of claim 1 or claim 2 , wherein the solvent-exposed, antibody accessible knuckle region of oligomeric Aβ corresponds to residues 25 to 29 of oligomeric Aβ (1-40) or residues 25 to 29 of oligomeric Aβ (1-42).

4. The antigenic peptide of claim 1 , wherein the antigenic peptide has an amino acid sequence of SEQ ID NO: 8.

5. An immunogenic composition comprising the antigenic peptide of claim 1 and a pharmaceutically acceptable adjuvant.

6. A method of treating or delaying the onset of Alzheimer's Disease in a patient in need of said treatment comprising administering said immunogenic composition of claim 5 .

7. An immunogenic composition comprising the antigenic peptide of claim 3 and a pharmaceutically acceptable adjuvant.

8. A method of treating or delaying the onset of Alzheimer's Disease in a patient in need of said treatment comprising administering said immunogenic composition of claim 7 .

9. The immunogenic composition of claim 5 , wherein the conformational epitope of the antigenic peptide has an amino acid sequence corresponding to SEQ ID NO: 1.

10. A method of treating or delaying the onset of Alzheimer's Disease in a patient in need of said treatment comprising administering said immunogenic composition of claim 9 .

11. The immunogenic composition of claim 5 , wherein the antigenic peptide has an amino acid sequence corresponding to SEQ ID NO: 8.

12. A method of treating or delaying the onset of Alzheimer's Disease in a patient in need of said treatment comprising administering said immunogenic composition of claim 11 .

Assignees

• Univ British Columbia

Inventors

• Cashman Neil R

Classifications

• A61P37/04

  Immunostimulants · CPC title

• C07K16/24

  against cytokines, lymphokines or interferons · CPC title

• G01N2333/4709

  Amyloid plaque core protein · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title